54.65
0.00 (0.00%)
| Previous Close | 54.65 |
| Open | 54.65 |
| Avg. Volume (3M) | 2,687,748 |
| Market Cap | 4,499,031,040 |
| Price / Book | 4.70 |
| 52 Weeks Range | |
| Earnings Date | 10 Nov 2025 |
| Diluted EPS (TTM) | -3.75 |
| Total Debt/Equity (MRQ) | 3.34% |
| Current Ratio (MRQ) | 16.80 |
| Operating Cash Flow (TTM) | -262.63 M |
| Levered Free Cash Flow (TTM) | -177.47 M |
| Return on Assets (TTM) | -18.52% |
| Return on Equity (TTM) | -27.92% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Akero Therapeutics, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -2.0 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | -5.0 |
| Technical Oscillators | 0.0 |
| Average | -1.25 |
|
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 1.37% |
| % Held by Institutions | 109.31% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |